Aumolertinib
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation (NCT05778149) | Tianjin Medical University Cancer Institute and Hospital | 2023-03-31 |
Track Aumolertinib automatically
Every clearance here is in the API, with alerts when new ones post.